Kaliumchloride

Potassium chloride, the active ingredient in Kaliumchloride, is an electrolyte supplement presented as an intravenous solution for intravenous use. It restores extracellular potassium levels, treating hypokalemia and potassium depletion, and helps prevent cardiac arrhythmias associated with low potassium in adult patients.

GNH USA supplies Kaliumchloride as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU pharmacopeial standards and is manufactured under GMP conditions, and it is distributed through a regulated supply chain ensuring quality and traceability.

Kaliumchloride, an electrolyte replacement administered intravenously, is used to correct potassium deficits.

Hypokalemia: restores normal serum potassium levels, reducing muscle weakness and cardiac disturbances. Potassium depletion: replenishes intracellular and extracellular potassium stores during acute loss. Prevention of cardiac arrhythmias due to low potassium: maintains cardiac electrical stability in at‑risk patients. Acute care settings: provides rapid potassium repletion during surgery, trauma or intensive‑care management.

Potassium chloride administered intravenously may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain: mild discomfort or burning at the infusion site. - Hyperkalemia: transient elevation of serum potassium if administered too rapidly. - Nausea or vomiting: gastrointestinal upset occurring shortly after infusion. - Metallic taste: transient taste disturbance during infusion.

Serious or Rare Side Effects: - Cardiac arrhythmia: life‑threatening rhythm disturbances due to rapid potassium rise. - Anaphylaxis: rare severe allergic reaction with hypotension, bronchospasm, or urticaria. - Phlebitis: inflammation of the vein at the infusion site.

When using Kaliumchloride, clinicians should observe several safety measures to minimize risk. - Renal function assessment: evaluate kidney function before and during therapy to avoid potassium accumulation. - Serum potassium monitoring: check levels frequently to maintain target range and prevent hyperkalemia. - Infusion rate control: administer over recommended time to reduce risk of cardiac events. - Concomitant drug review: avoid simultaneous use with other potassium‑containing products or ACE inhibitors without monitoring. - Contraindications: do not use in patients with severe hyperkalemia or untreated digitalis toxicity. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, and retain in original packaging.

Potassium chloride can interact with several medicines, altering potassium balance or cardiac effects.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may cause additive hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of dangerous potassium excess. - Digoxin: heightened risk of digoxin toxicity when serum potassium is high.

Moderate Interactions (Monitor Closely): - Non‑potassium‑containing diuretics: may require dose adjustments of potassium chloride. - NSAIDs: can reduce renal potassium excretion, necessitating closer monitoring. - Beta‑blockers: may mask symptoms of hyperkalemia, requiring vigilant serum checks.